Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
0 hedge funds and large institutions have $143K invested in Sonnet BioTherapeutics in 2018 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
51% less capital invested
Capital invested by funds: $294K → $143K (-$151K)
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$110K |
| 2 |
AG
Advisor Group
Phoenix,
Arizona
|
-$21K |
| 3 |
SCM
Stumpf Capital Management
Scottsdale,
Arizona
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Citadel Advisors
Miami,
Florida
| $26K | – | – | – |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $26K | – | – | – |
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $19K | – | – | – |
|
|
IC
4
Intersect Capital
San Ramon,
California
| $16K | – | – | – |
|
5
Dimensional Fund Advisors
Austin,
Texas
| $15K | – | – | – |
|
|
VF
6
Virtu Financial
New York
| $15K | – | – | – |
|
7
BlackRock
New York
| $13K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $7K | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $4K | – | – | – |
|
10
Macquarie Group
Sydney, NSW 2000,
Australia
| $1K | – | – | – |
|
|
QCIG
11
Quad-Cities Investment Group
Davenport,
Iowa
| $1K | – | – | – |
|
|
PCM
12
Perkins Capital Management
Wayzata,
Minnesota
| – | -$110K | -1 | Closed |
|
|
AG
13
Advisor Group
Phoenix,
Arizona
| – | -$21K | – | – |
|
|
SCM
14
Stumpf Capital Management
Scottsdale,
Arizona
| – | -$5K | – | – |
|
SONN Hedge Fund Activity: Q4 2018 in Review
0 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q4 2018, worth a combined $143K — down 51% from $294K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SONN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Perkins Capital Management, exiting entirely with an estimated $110K sold.
- 0 institutional investors held Sonnet BioTherapeutics (SONN) as of Q4 2018, down from 1 in Q3 2018.
- Funds reported $143K of Sonnet BioTherapeutics stock for Q4 2018, down 51% quarter-over-quarter.
- 0 funds opened new Sonnet BioTherapeutics positions in Q4 2018 and 1 closed out, a net change of -1 holder.
- The largest Sonnet BioTherapeutics seller in Q4 2018 was Perkins Capital Management, an estimated $110K sold.
Based on aggregated 13F filings for Q4 2018.